Ver bibliografía utilizada

Ver otra bibliografía de interés


Bibliografía utilizada en la sección Elecsys ß-CrossLaps de este sitio web.

  • Yao L, Sayre JW. Statistical concepts in the interpretation of serial bone densitometry. Invest Radiol 1994;29(10):928-32 Link. Ir a sitio web
  • Wolff I et al. The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int. 1999;9(1):1-12. Ir a sitio web
  • Christgau et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone, 2000;26:505-511. Ir a sitio web
  • Garnero P, Sornay-Rendu E, Duboeuf F, Delmas F. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study. J Bone Miner Res 1999;14:1614–1621. Ir a sitio web
  • Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 2000; Suppl 6:55-65. Ir a sitio web
  • Homik J et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000;(2):CD001347. Ir a sitio web
  • Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001;47(4):694-702.
  • Kleerekoper M. Biochemical markers of bone turnover: why theory, research, and clinical practice are still in conflict. Clin Chem. 2001 Aug;47(8):1347-9.
  • Okabe R et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem 2001;47(8):1410-4.
  • Germán M. Guevara F. Controversias en el diagnóstico de Osteoporosis Volumen 16 No. 3 julio - septiembre de 2002 Revista de la Asociación Colombiana de Gerontología y Geriatría.
  • La Atención Primaria pide más recursos para el diagnóstico de las enfermedades más prevalentes. Nº 51- febrero 2003 - pág 135 - 143 Revista de la SEMG.
  • Bruyere O et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 2003;44(4):259-65. Ir a sitio web
  • Tanko et al. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 2003;32: 687-693. Ir a sitio web
  • ß-CrossLaps for efficient disease management and early detection of osteoporosis. Roche Diagnostics 03754740.
  • Henriksen G E et al. Prediction of skeleton response to bisphosphonate therapy using serum CrossLaps One Step Elisa (Poster).
  • Bone markers and osteoporosis. Elecsys® ß-CrossLaps (serum). Roche Diagnostics 499-1958658(2).

Otra bibliografía de interés

  • Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004 Jan 7;291(1):47-53. Ir a sitio web
  • Okabe R et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline. J Bone Miner Metab. 2004;22(2):127-31. Ir a sitio web
  • Rosen HN, Parker RA, Greenspan SL, Iloputaife ID, Bookman L, Chapin D, Perlmutter I, Kessel B, Qvist P, Rosenblatt M. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcif Tissue Int. 2004 May;74(5):415-23. Epub 2004 Feb 17. Ir a sitio web
  • Schmidt-Gayk H et al. Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med. 2004;42(1):90-5. Ir a sitio web
  • Black DM et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003 Sep 25;349(13):1207-15. Ir a sitio web
  • Christiansen C et al. Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int. 2003;14(7):609-13. Ir a sitio web
  • Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res. 2003 Oct;18(10):1789-94. Ir a sitio web
  • Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc. 2003 Mar;9(1):10-5. Ir a sitio web
  • Tanko LB, Mouritzen U, Lehmann HJ, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N, Christiansen C. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone. 2003 Jun;32(6):687-93. Ir a sitio web
  • Sornay-Rendu E et al. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone. 2003;33(1):159-66. Ir a sitio web
  • Stepan JJ et al. Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta. 2003;336(1-2):49-55. Ir a sitio web
  • Clowes JA et al.Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002 Jun;30(6):886-90. Ir a sitio web
  • Garnero P et al. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. J Clin Pharmacol. 2002;42(3):290-6. Ir a sitio web
  • Green JH et al. Impact of supplementary high calcium milk with additional magnesium on parathyroid hormone and biochemical markers of bone turnover in postmenopausal women.Asia Pac J Clin Nutr. 2002;11(4):268-73. Ir a sitio web
  • Rosenbrock H, Seifert-Klauss V, Kaspar S, Busch R, Luppa PB. Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med. 2002 Feb;40(2):143-51. Ir a sitio web